Hide filtersShow filters × Close Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Medartis’ IPO CHF142.6 million on SIX Swiss Exchange Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement Bryan Garnier & Co acts as Global Coordinator for Biom’Up’s financing representing a total amount of more than €40 million Bryan, Garnier & Co acts as Co-manager for Ablynx Nasdaq IPO raising USD 230 million Bryan Garnier & Co acts as Sole Global Coordinator for Biom’Up’s landmark Euronext IPO, raising up to €44 million including greenshoe Bryan, Garnier & Co acts as Joint Bookrunner of a private placement with US and European Investors raising €18 Million for Oryzon Upon pricing its landmark IPO on Euronext Paris led by Sole Global Coordinator Bryan, Garnier & Co, Symetis is acquired by Boston Scientific for USD 435 million Bryan, Garnier & Co announces the successful USD 22 million / DKK 143 million follow-on offering for Zealand Pharma Bryan, Garnier & Co annouces the successful closing of Soitec’s €75.4 million Rights Issue Rights Issue Sandnes Sparebank ASA Bryan, Garnier & Co announces a €14.7m follow-on offering for Amoeba on Euronext with demand from European and US investors
